MORRISVILLE, N.C.--(BUSINESS WIRE)--ParagonDx, LLC, a leader in genetic testing diagnostics, has formed a strategic alliance with Iverson Genetic Diagnostics Inc., a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory based in Seattle. Under the terms of the agreement, Iverson Genetics will use ParagonDx’s products to test patients to determine if they possess genetic traits shown to increase or decrease sensitivity to warfarin. Warfarin is a blood thinner that prevents and treats blood clots and is also known as Coumadin.
